The 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008
1 Patterns of prior viral suppression on cART as predictors of future risk of viral rebound. J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, JD Lundgren
Poster 90 KB
2 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients. W Bannister, A Mocroft, O Kirk, P Reiss, A d´Arminio-Monforte, J Gatell, M Fischer, H Trocha, A Rakhmanova, and JD Lundgren.
Poster 110 KB
3 The rate of change of CD4 count (CD4 slopes) in patients with stable HIV viremia currently taking combination antiretroviral therapy or off all antiretrovirals. A Mocroft, AN Phillips, B Ledergerber, J Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 99 KB
4 Predicting the short term risk of diabetes in HIV infected patients in the D:A:D cohort: The D:A:D study group. K Petoumenos, E Fontas, SW Worm, R Weber, S De Wit, M Bruyand, CA Sabin, P Reiss, W El-Sadr, A D´Arminio-Monforte, N Friis-Møller, JD Lundgren, M Law on behalf of the D:A:D study group.
Poster 152 KB
5 The relationship between an adverse effect of antiretroviral treatment and underlying risk in number needed to treat to harm - risk of myocardial infarction and abacavir use. J Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss, JD Lundgren
Poster 249 KB
6 Poor clinical oputcome in HIV-infected patients coinfected with mycobacterium tuberculosis (TB) in Eastern Europe. The HIV/TB collaborative study. D Podlekareva, A Mocroft, F Post, V Riekstina, J Miro, H Furrer, M Bruyand, E Malashenkov, E Girardi, JJ Toibaro, J Cayla, R Miller, N Obel, A Skrahin, N Chentsova, JD Lundgren, O Kirk and the HIV/TB study group.
Poster 251 KB
1 Are non-B subtypes less susceptible to antiretroviral drugs? - a bioinformatical approach to prediction on non-B subtype susceptibility. J Kjær, L Høj, N Friis-Møller, P Reiss, JD Lundgren
Poster 249 KB
XVII International AIDS Conference, Mexico City, August 2008
1 Use of nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. JD Lundgren and the SMART/INSIGHT and D:A:D Study Groups.
Slides 127 KB
2 TB and injecting drug use in Eastern Europe Clinical and Epidemiological Aspects and Implications for Public Health. D. Podlekareva
Slides 716 KB
Polish National Conference on HIV, Warsaw, June 2008
1 Risk of myocardial infarction attributable to abacavir: Analysis to assess the number needed to treat to harm. Justyna D. Kowalska, Ole Kirk, Amanda Mocroft, Jens D. Lundgren
Poster 239 KB
XVII International HIV Drug Resistance Workshop, Sitges, June 2008
1 In silico identification of physiochemical properties at mutating positions relevant to reduced susceptibility to amprenavir. L Høj, J Kjær, O Winther, A Cozzi-Lepri and JD Lundgren.
Poster No.113 104 KB
2 The rate of accumulation of NNRTI-resistance in patients kept on a virologically failing regimen containing NNRTI: a EuroSIDA Study. A Cozzi-Lepri, B Clotet, R Paredes, J Kjær, AN Phillips, and JD Lundgren for the EuroSIDA study group.
Poster No.128 154 KB
3 Treatment-ermergent gag cleavage site mutations during virological failure of ritonavir-boosted protease-inhibitors. A Garcia- Diaz, Z Fox, UB Dragsted, J Kjær, N Clumeck, A Phillips, JD Lundgren and AM Geretti.
15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008
1 The use and response to second combination antiretroviral therapy (cART) regimens in EuroSIDA. A Cozzi-Lepri, M Cunnington, A Lazzarin, B Clotet, B Knysz, P Gargalianos, C Katlama, A Karlsson, AN Phillips, J D Lundgren
Poster No. 797 129 KB
2 What frequency of monitoring is needed for health-care in a HIV-infected person?J Reekie, B Gazzard, H Sambatakou, A Chiesi, J van Lunzen, N Clumeck, O Kirk, A Mocroft, L Machala, J Lundgren
Poster No. 808 104 KB
3 Indicators of the use of health care interventions across Europe. D Podlekareva, J Reekie, A Rakhmanova, A Horban, A Mocroft, I Karpov, P Domingo, F Antunes, O Kirk, JD Lundgren and the EuroSIDA study group
Poster No. 811 157 KB
4 Do Thymidine Analogues, Abacavir, Didanosine and Lamivudine Contribute to the Risk of Myocardial Infarction (MI)?
Recent Use of Abacavir and Didanosine, but not of Thymidine Analogues, Is Associated with Risk of Myocardial Infarction. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W El-Sadr, R Thiebaut, S De Wit, M Law, A D’Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, S Collins, I Weller, AN Phillips, JD Lundgren on behalf of the D:A:D study group
Poster No. 957c 121 KB
5 Deterioration of renal function (DRF) associated with current level of immunodeficiency. O Kirk, A Mocroft, A d’Armino Monforte, A-BE Hansen, JM Gatell, S Caplinskas, G Fätkenheuer, P Reiss, E Vinogradova, JD Lundgren for the EuroSIDA study group.
Poster No. 971 133 KB
6 Characteristics and clinical outcome of patients with HIV-associated tuberculosis (HIV/TB) in Europe and Argentina. D Podlekareva, A Mocroft, A Panteleev, J Toibaro, A Rakhmanova, V Riekstina, H-J Furrer, O Suetnov, F Post, O Kirk and the HIV/TB Study Group
Poster No. 1000 197 KB
7 Hepatitis C virus (HCV) coinfection does not influence the CD4 cell recovery in HIV infected patients with maximum virologic suppression within the EuroSIDA cohort. L Peters, A Mocroft, V Soriano, J Rockstroh, P Aldins, M Losso, L Valerio, P Reiss, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster No. 1069 102 KB
8 Hepatitis Virus Co-infections and Risk of Diabetes Mellitus (DM) and Myocardial Infarction (MI) in HIV-infected Persons: The D:A:D Study.R Weber, C Sabin, P Reiss, S De Wit, S Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, J Lundgren
Poster No. 1082 82 KB
1 Re-initiation of antiretroviral therapy (ART) in the CD4-guided ART interruption group in the SMART study lowers risk of opportunistic disease or death. W El-Sadr and the SMART study group
Abstract No. 36
2 Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. L Kuller and the SMART study group
Abstract No. 139
3 Age/sex-specific death rates in ART naïve patients with CD4 count above 350 cells/mm3 compared with the general population. R Lodwick, K Porter, C Sabin, B Ledergerber, A Cozzi-Lepri, P Khaykin, A Mocroft, L Jacobson, S de Wit, A Phillips on behalf of the Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients
Updated: 10 Nov 2008